Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GS-6207 in heavily treatment-experienced people with multidrug-resistant HIV-1
2019-003814-16Phase 2Recruiting
- Sponsor
- Gilead Sciences
- Start
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenacapavir in Human immunodeficiency virus infection type 1, sponsored by Gilead Sciences. Primary endpoint: Proportion achieving at least 0.5 log10 reduction in HIV-1 RNA at end of functional monotherapy period. Started Dec 2019; status: recruiting.
02
Drugs
lenacapavir
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2019-003814-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003814-16.